LONDON–(BUSINESS WIRE)–Curaleaf International (the “Company”), the largest vertically integrated cannabis company in Europe, welcomes the results of a new European survey and report on the European recreational cannabis market, the first of its kind by Hanway Associates, a consulting firm specializing in strategy, research and M&A in the cannabis sector.
Polling data released by Hanway Associates reveals that there is majority support across Europe for legal and government-regulated sales of cannabis products to adults over the age of 18. Overall, of the 9,043 adults surveyed, 55% supported legal recreational cannabis, 20% were indifferent, and the remaining 25% opposed it. Companies’ adherence to the highest service and regulatory standards in their approach to legal recreational cannabis was of particular importance to Europeans. This is why a regulated retail offering is the least controversial option among supporters of legal recreational cannabis with 81% in favor of legal recreational cannabis. clubs (56% support) and local products (62% support). Of all survey respondents, 48% support regulated retail stores, 35% support local products, and 32% support social clubs. Home Grown has the strongest opposition with 41% against among all respondents. These results point to promising business opportunities for highly regulated stores and products.
Antonio Costanzo, CEO of Curaleaf International, said: “This report clearly shows that the majority of Europeans want recreational cannabis to be available in a way that gives adults access to high-quality, regulated products. As the largest vertically integrated cannabis company in Europe with a offering market-leading medical cannabis in nine European countries, I believe Curaleaf International is uniquely positioned to capitalize on this opportunity.In addition, our parent company, Curaleaf Holdings, operates a multi-state operator model in the United States. which can be replicated in Europe to give us a significant first-mover advantage.
Joe Bayern, CEO of Curaleaf, said: “This report proves what Curaleaf has been saying for some time now, which is that Europeans want access to safe, competitively priced, high quality cannabis that is legal. The next step is for legislation to catch up with consumer demand. Fortunately, we are seeing promising actions by several governments. The new German government which is committed to legalizing recreational cannabis is an inflection point for the market since it represents the largest economy in Europe. Once Germany leaves, the rest of the continent will likely follow. Curaleaf, through Curaleaf International, prides itself on being a leading provider of the highest quality cannabis products for European patients and consumers. »
– Ends –
About Curaleaf International
Curaleaf International (formerly EMMAC Life Sciences Group) is the largest vertically integrated cannabis company in Europe, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network across Europe, Curaleaf International’s vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021.
For more information about Curaleaf International, please visit: https://www.curaleafinternational.com
Several sources of data have been used to support the information in this report.
- One-of-a-kind pan-European survey
This report marks the launch of The European Cannabis Legalization Tracker, the first annual pan-European opinion poll on recreational cannabis.
Savanta ComRes surveyed a nationally representative sample of 9,043 adults aged 18+ across eight European markets in France, Germany, Italy, Spain, the Netherlands, Portugal, Switzerland and the UK between February 24and and March 14and. Data was weighted to be representative of gender, age and region.
All statements, other than statements of historical facts, contained in this press release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, future plans and objectives. of Curaleaf International. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the short term.
Actual results and future events could differ materially from those anticipated in these statements. These written and oral forward-looking statements and all subsequent forward-looking statements are based on management’s estimates and opinions as of the dates they are made and are expressly qualified in their entirety by this notice. Curaleaf International undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions change.